Related Experiment Video
Updated: May 17, 2026
09:12
Optimization of Processing of Tiebangchui with Highland Barley Wine Based on the Box-Behnken Design Combined with the Entropy Method
Published on: May 19, 2023
Bachelor's degree programs in clinical pharmacy in China
Junhao Jiang1, Yan Liu, Ping Deng
1The School of Pharmacy, Chongqing Medical University, Chongqing, China.
American Journal of Pharmaceutical Education
|November 7, 2012
Summary
Clinical pharmacy education in China is expanding, with 23 colleges offering bachelor
Area of Science:
- Pharmacy Education
- Health Professions Education
- Higher Education in China
Background:
- Clinical pharmacy education is crucial for advancing healthcare.
- China has seen growth in its healthcare sector, increasing demand for skilled pharmacists.
- Understanding the current state of clinical pharmacy programs is essential for future development.
Purpose of the Study:
- To assess the current status of bachelor's degree programs in clinical pharmacy in China.
- To analyze educational institutions, program structures, and curricula.
- To identify areas for improvement in clinical pharmacy education.
Main Methods:
- Systematic literature review of articles published between 2006 and 2011.
- Direct contact (email/phone) with colleges for curriculum data.
- Analysis of program duration, degree types, and institutional offerings.
Main Results:
- Twenty-three Chinese colleges offered clinical pharmacy programs in 2011.
- Programs award Bachelor of Science (BS) or Bachelor of Medicine (BM) degrees.
- The 5-year BS degree program was the most prevalent.
Conclusions:
- The number of clinical pharmacy programs in China is increasing.
- There is a need for more graduates to meet healthcare demands.
- Standardization of curricula is required to ensure quality healthcare education.
Related Concept Videos
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:19Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...